University of Washington

Cambridge Enterprise Limited

Jiao, Alex

Kim, Deok-ho

Gupta, Kshitiz

Murry, Charles

Laflamme, Michael

Yoo, Hyok

Charles E Murry

Michael Laflamme

Lil Pabon

Nathan Palpant

Michael Regnier

Jeffrey S Chamberlain

Nathan J Sniadecki

Xuan Guan

Deok-Ho Kim

Sanjay Sinha

Stephen Denison Hauschka

Alex Jiao

Kevin S Bielawski

Andrea B Leonard

Guy Odom

Kshitiz Gupta

Johannes Bargehr

Hyok Yoo

Shiv Bhandari

F Steven Korte

Scott Lundy

Provided herein are isolated nucleic acids that encode a stable form of Rrm2 for the use of increasing the intracellular Rrm2 protein levels and cytosolic 2-deoxy-ATP (dATP) levels. Further provided herein are methods for treating a cardiac disease or disorder, e.g., myocardial infarction or myocardial ischemia, by administering the isolated nucleic acids, a polypeptide encoded by the isolated nucleic acids, or composition comprising the isolated nucleic acids to a subject in need thereof.

Engineering the RRM2 subunit of ribonucleotide reductase to resist degradation

Provided herein are methods that enable the polarization of hPSC mesoderm such that closely related yet distinct cardiovascular populations can be generated efficiently without the need of post-facto enrichment.

Human pluripotent stem cell derived endocardial endothelium

Provided herein are methods and compositions comprising cardiomyocytes and epicardial cells for the treatment of cardiac disease.

Methods and compositions for enhancing cardiomyocyte maturation and engraftment

Devices and techniques for magnetic detection of myocardial forces are generally described. In some examples, cardiac tissue may be cultured such that the cardiac tissue adheres to a first post and a second post. In further examples, a magnetometer may detect a change in a magnetic field resulting from a deflection of the first post in a first direction from a first position to a second position. In some other examples a signal corresponding to the change in the magnetic field may be generated. In still other examples, frequencies of the signal outside of a first frequency range may be excluded to produce a filtered signal. In various examples, the first frequency range may include frequencies associated with beating of cardiac tissue. In still further examples, a force exerted by the cardiac tissue may be determined based at least in part on the filtered signal.

System for magnetic detection of myocardial forces

The present invention generally relates to the field of cell growth and tissue engineering, in particular, tissue engineered compositions comprising a nanotextured substrate which is structurally configured for growth of cells in an anatomically correct adult phenotype in vitro. In particular, described herein are nanotextured substrates which are structurally configured for the anisotropic organization, maturation, and growth of in vitro-differentiated muscle cells, such as cardiomyocytes, and methods for the production and use thereof in varying sizes, nanotextures and substrate rigidities. In vitro-differentiated cardiomyocytes grown on the nanotextured substrates described herein are better-differentiated and more closely mimic adult cardiac tissue than the same cells grown on a non-textured substrate of the same composition. The nanotextured substrate/cell constructs provide a platform for screening to predict the effect of test agents or drugs on, for example, human cardiac tissue, including patient-derived tissue, or for the identification of agents that effect various cardiac functional parameters.

Systems and method for engineering muscle tissue

Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.

Cell and gene based methods to improve cardiac function

The survival of cells during transplantation is enhanced. Cells to be transplanted are administered in a formulation that provides two ore more survival enhancing factors. Optionally, prior to administration, the cells are cultured in the presence of factors that enhance survival, and may be heat shocked prior to transplantation.

Formulation to improve survival of transplanted cells

Growing community of inventors

Seattle, WA, United States of America

Charles E Murry